The Global business research report published on “Primary Biliary Cirrhosis Drugs Market – Growth Drivers, Challenges Ahead, Industry Insights, Supply, Revenue Analysis, Trends, and Forecasts 2021 -2027“. The Primary Biliary Cirrhosis Drugs research report covers the present scenario and the growth prospects of the global Primary Biliary Cirrhosis Drugs industry for 2018-2026. The report enlists several important factors, starting from the basics to advanced market intelligence which play a crucial part in strategizing. Primary Biliary Cirrhosis Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Primary Biliary Cirrhosis Drugs industry.
The report classifies the market into different segments based on technique, application and end-user. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.
Request for Analysis of COVID-19 Impact on Primary Biliary Cirrhosis Drugs Market – https://www.coherentmarketinsights.com/insight/request-sample/1539
Geographically, The market has been segmented into 5 major regions, namely: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. The report clears present and coming business sector patterns, development, income, deals, utilization, purchaser desires, sales, CAGR, and venture esteem. The report compares this knowledge about the market aspects with the current state of the market and discusses the forthcoming trends that have brought market progression.
Primary biliary cirrhosis (PBC) also called primary biliary cholangitis is an autoimmune disease of liver, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. PBC causes autoimmunity, infection and/or genetic predisposition. The primary symptoms of primary biliary cirrhosis are itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. PBS develops over the time and eventually causes the liver to stop working completely in later stages. Most people are diagnosed early, before the disease progresses. Delay in treatment of cirrhosis can cause liver failure and a liver transplant is necessary for survival. Diagnostic tests for primary biliary cirrhosis includes examination of elevated levels of IgM immunoglobulin levels, lipids, cholesterol and bilirubin, liver biopsy, ultrasonography, CT scanning or MRI. Increasing research and development activities and rising incidence of primary biliary cirrhosis is expected to be a major driver for growth of the primary biliary cirrhosis drugs market.
Market Dynamics- Drivers
Currently, only two U.S. Food and Drug Administration (FDA)-approved drugs, Ursodeoxycholic acid and Ocaliva, are available in market to reduce cirrhosis progression. However, large number of drugs are in pipeline, which is expected to propel growth of the global primary biliary cirrhosis drug market during the forecast period. For instance, in 2017, NGM Biopharmaceuticals, Inc. completed phase II clinical trials for its candidate drug NGM 282, an engineered variant of human hormone FGF19, to eliminate bile acid toxicity in primary biliary cirrhosis patients. NGM282 has a unique opportunity to leverage the dual targets of FGF19 without the potential non-tumorigenic property.
Ask for PDF sample copy of the Primary Biliary Cirrhosis Drugs market report @ https://www.coherentmarketinsights.com/insight/request-pdf/1539
Growing U.S. FDA-approvals for novel drugs is expected to drive the global primary biliary cirrhosis drug market growth in the near future. For instance, in 2016, Intercept Pharmaceuticals, Inc., received the U.S. FDA approval for its Ocaliva, obeticholic acid based drug, in combination with ursodeoxycholic acid for adults with inadequate response to ursodeoxycholic acid based monotherapy for the treatment of primary biliary cirrhosis. As on March 2018, University of Florida is investigating Fenofibrate Insoluble Drug Delivery – Micro Particle on patients with incomplete response to ursodeoxycholic acid. Moreover, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, is investigating Bezafibrate in combination with ursodeoxycholic acid for the treatment of primary biliary cirrhosis, which is in phase III clinical trials as on 2016. Furthermore, from the same source, it is estimated that 30 to 50% of patients with primary biliary cirrhosis shows partial response to ursodeoxycholic acid, which demands for combinational treatment. Janssen Research and Development also evaluated efficacy and safety of Ustekinumab for primary biliary cirrhosis with inadequate response to ursodeoxycholic acid. The research was in phase II clinical trial as of June 2016. These increasing pipeline products are expected to aid in growth of the primary biliary cirrhosis drugs market over the forecast period.
Furthermore, growing occurrence of primary biliary cirrhosis is expected to accelerate growth of the global primary biliary cirrhosis drugs market. Primary biliary cirrhosis occurs in patients aged 40–60 years and affects women more often than men. According to American Association for the Study of Liver Diseases (AASLD) published in 2016, prevalence of primary biliary cirrhosis (PBC) in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons. In UK, the prevalence of PBC is estimated to be 12.9 per 100,000 population, of which 90% of cases where reported in women. Furthermore, increasing incidence of autoimmune disease, tobacco smoking, tonsillectomy or urinary tract infection (in women) are risk factors, for primary biliary cirrhosis.
Based on geography, the primary biliary cirrhosis drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Among regions, North America holds dominant position in the global primary biliary cirrhosis drugs market. This is owing to increasing research and developmental activities by market players in the region. For instance, Enanta Pharmaceutical, Inc. is examining its EDP – 305, a potent FXR agonist for the treatment of primary biliary cirrhosis, which was in phase II clinical trials in 2017. However, Asia Pacific is expected to witness fastest growth in primary biliary cirrhosis drugs market due to high incidence of liver cirrhosis in the region. According to article published in 2014 of BMC medicine, mortality from liver cirrhosis was also comparatively high in Central Asia countries, particularly Mongolia, Uzbekistan and Kyrgyzstan,
Reasons to Purchase this Report
• Current and future of global Primary Biliary Cirrhosis Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Buy Now This Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1539
Global Primary Biliary Cirrhosis Drugs Market – Competitor
Key players in the global primary biliary cirrhosis drugs market are Intercept Pharmaceuticals, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Dr. Falk Pharma GmbH, and Enanta Pharmaceuticals, Inc.
Global Primary Biliary Cirrhosis Drugs Market – Taxonomy
By Drug Type
- Ursodeoxycholic acid (USDA)
- Obeticholic acid
- Others (anti-inflamatory, anti-pruritics, and anti-histamines)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Main points in Primary Biliary Cirrhosis Drugs Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Primary Biliary Cirrhosis Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Primary Biliary Cirrhosis Drugs Industry Impact
Chapter 2 Global Primary Biliary Cirrhosis Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Primary Biliary Cirrhosis Drugs (Volume and Value) by Type
2.3 Global Primary Biliary Cirrhosis Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Primary Biliary Cirrhosis Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 6 East Asia Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 7 Europe Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 8 South Asia Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 9 Southeast Asia Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 10 Middle East Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 11 Africa Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 12 Oceania Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 13 South America Primary Biliary Cirrhosis Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Primary Biliary Cirrhosis Drugs Business
Chapter 15 Global Primary Biliary Cirrhosis Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027